Registro de pacientes con distrofinopatías en Colombia

dc.contributorMateus Arbelaez, Heidi Eliana
dc.creatorEslava Otálora, Andrea Cecilia
dc.date.accessioned2016-08-31T13:26:24Z
dc.date.available2016-08-31T13:26:24Z
dc.date.created2016-08-31T13:26:24Z
dc.date.issued2016
dc.identifierhttp://repository.urosario.edu.co/handle/10336/12351
dc.identifierhttps://doi.org/10.48713/10336_12351
dc.description.abstractINTRODUCTION. Duchenne muscular dystrophy is a neuromuscular disease with X-linked recessive inheritance that affects 1 in 3, 500 live births. It is caused by mutations in the DMD gene coding for dystrophin. It is characterized by typical variable clinical manifestations of progressive proximal muscular dystrophy. OBJECTIVE. Perform the first registry in Colombia of patients identified with dystrophinopathies, taking into account clinical and paraclinical characteristics and causal mutations of this disease. METHODOLOGY It is a transversal, descriptive study of the review of medical records of patients diagnosed with DMD treated at the Genetics unit at the University of Rosario during the years 2006-2015. RESULTS 99 patients were identified, of which 56 (56. 56%) correspond to Duchenne phenotype and 12 (12. 12%) to Becker. It was not possible to classify 31 patients (31. 3%) due to lack of clinical data. The age of onset of symptoms was on average 4. 41 years. The most frequent mutations were deletions (69%), followed by point mutations (14%), duplication (11%) and other mutations (4%). CONCLUSIONS This registry of dystrophinopathies is the first reported in Colombia and the starting point to determine the incidence of the disease, clinical and molecular characterization of patients, ensuring timely access to new medical treatments precision to improve the quality of life of patients and their families
dc.languagespa
dc.publisherUniversidad del Rosario
dc.publisherMaestría en Ciencias con Énfasis en Genética Humana
dc.publisherFacultad de medicina
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto completo)
dc.rightsEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.sourceAartsma-rus, A., Bremmer-bout, M., Janson, A. A. M., Dunnen, J. T. Den, Ommen, G. B. Van, & Deutekom, J. C. T. Van. (2002). Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy, 12.
dc.sourceAartsma-Rus, A., Ferlini, A., & Vroom, E. (2014). Biomarkers and surrogate endpoints in Duchenne: Meeting report. Neuromuscular Disorders, 24(8), 743–745. http://doi.org/10.1016/j.nmd.2014.03.006
dc.sourceAartsma-Rus, A., Fokkema, I., Verschuuren, J., Ginjaar, I., Van Deutekom, J., Van Ommen, G. J., & Den Dunnen, J. T. (2009). Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Human Mutation, 30(3), 293–299. http://doi.org/10.1002/humu.20918
dc.sourceAartsma-rus, A., Ginjaar, I. B., & Bushby, K. (2016). The importance of genetic diagnosis for Duchenne muscular dystrophy, 1–7. http://doi.org/10.1136/jmedgenet-2015-103387
dc.sourceAartsma-Rus, A., Van Deutekom, J. C. T., Fokkema, I. F., Van Ommen, G. J. B., & Den Dunnen, J. T. (2006). Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle and Nerve, 34(2), 135–144. http://doi.org/10.1002/mus.20586
dc.sourceAbbs, S., Tuffery-Giraud, S., Bakker, E., Ferlini, A., Sejersen, T., & Mueller, C. R. (2010a). Best practice guidelines on molecular diagnostics in Duchenne/Becker muscular dystrophies. Neuromuscular Disorders : NMD, 20(6), 422–7. http://doi.org/10.1016/j.nmd.2010.04.005
dc.sourceAbbs, S., Tuffery-Giraud, S., Bakker, E., Ferlini, A., Sejersen, T., & Mueller, C. R. (2010b). Best practice guidelines on molecular diagnostics in Duchenne/Becker muscular dystrophies. Neuromuscular Disorders : NMD, 20(6), 422–7. http://doi.org/10.1016/j.nmd.2010.04.005
dc.sourceBladen, C. L., Rafferty, K., Straub, V., Monges, S., Moresco, A., Dawkins, H., … Lochmüller, H. (2013). The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Human Mutation, 34(11), 1449–57. http://doi.org/10.1002/humu.22390
dc.sourceBladen, C. L., Salgado, D., Monges, S., Foncuberta, M. E., Kekou, K., Kosma, K., … Lochmüller, H. (2015). The TREAT-NMD DMD global database: Analysis of more than 7,000 duchenne muscular dystrophy mutations. Human Mutation, 36(4), 395–402. http://doi.org/10.1002/humu.22758
dc.sourceBorun, P., Kubaszewski, L., Banasiewicz, T., Walkowiak, J., Skrzypczak-Zielinska, M., Kaczmarek-Rys, M., & Plawski, A. (2014). Comparative-high resolution melting: A novel method of simultaneous screening for small mutations and copy number variations. Human Genetics, 133(5), 535–545. http://doi.org/10.1007/s00439-013-1393-1
dc.sourceBrabec, P., Vondráček, P., Klimeš, D., Baumeister, S., Lochmüller, H., Pavlík, T., & Gregor, J. (2009). Characterization of the DMD/BMD patient population in Czech Republic and Slovakia using an innovative registry approach. Neuromuscular Disorders, 19(4), 250–254. http://doi.org/10.1016/j.nmd.2009.01.005
dc.sourceBradley, D., & Parsons, E. (1998). Newborn screening for Duchenne muscular dystrophy. Seminars in Neonatology, 3(1), 27–34. http://doi.org/10.1016/S1084-2756(98)80146-2
dc.sourceBushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., … Constantin, C. (2010a). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurology, 9(1), 77–93. http://doi.org/10.1016/S1474-4422(09)70271-6
dc.sourceBushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., … Constantin, C. (2010b). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurology, 9(1), 77–93. http://doi.org/10.1016/S1474-4422(09)70271-6
dc.sourceBushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., … Constantin, C. (2010c). Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurology, 9(2), 177–89. http://doi.org/10.1016/S1474-4422(09)70272-8
dc.sourceChaustre, D. M., & Chona, W. S. (2011). Distrofia Muscular de Duchenne. Perspectivas Desde La Rehabilitación. Revista Facultad de Medicina, 19(1), 45–55.
dc.sourceCiafaloni, E., Fox, D. J., Pandya, S., Westfield, C. P., Puzhankara, S., Romitti, P. a, … Moxley, R. T. (2009). Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). The Journal of Pediatrics, 155(3), 380–5. http://doi.org/10.1016/j.jpeds.2009.02.007
dc.sourceConnolly, A. M., Florence, J. M., Cradock, M. M., Malkus, E. C., Schierbecker, J. R., Siener, C. a, … Eagle, M. (2013). Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network. Neuromuscular Disorders : NMD, 23(7), 529–39. http://doi.org/10.1016/j.nmd.2013.04.005
dc.sourceCowan, D. P. (2012). Guía De Práctica Clínica. Reu-30, (Enfermedad de Paget), 1–18.
dc.sourceEmery, A. E. H. & Emery, M. L. H. (1993). Edward Meryon (1809-1880) and muscular dystrophy. Journal of Medical Genetics, 30(6), 506–511. http://doi.org/10.1136/jmg.30.6.506
dc.sourceEn, C., & Emergencia, L. O. S. C. D. E. (n.d.). DIAGNÓSTICO Y MANEJO DE LA DISTROFIA MUSCULAR DUCHENNE , 1–36.
dc.sourceEsterhuizen, A. I., Wilmshurst, J. M., Goliath, R. G., & Greenberg, L. J. (2014). Duchenne muscular dystrophy: High-resolution melting curve analysis as an affordable diagnostic mutation scanning tool in a South African cohort. South African Medical Journal, 104(11), 779. http://doi.org/10.7196/samj.8257
dc.sourceFairclough, R. J., Wood, M. J., & Davies, K. E. (2013). Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nature Reviews. Genetics, 14(6), 373–8. http://doi.org/10.1038/nrg3460
dc.sourceFlanigan, K. M., Voit, T., Rosales, X. Q., Servais, L., Kraus, J. E., Wardell, C., … Wright, P. (2014). Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial. Neuromuscular Disorders, 24(1), 16–24. http://doi.org/10.1016/j.nmd.2013.09.004
dc.sourceGatheridge, M. A., Kwon, J. M., Mendell, J. M., Scheuerbrandt, G., Moat, S. J., Eyskens, F., … Griggs, R. C. (2015). Identifying Non-Duchenne Muscular Dystrophy-Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review. JAMA Neurology, 73(1), 1–7. http://doi.org/10.1001/jamaneurol.2015.3537
dc.sourceHegde, M. R., Chin, E. L. H., Mulle, J. G., Okou, D. T., Stephen, T., & Zwick, M. E. (2009). NIH Public Access, 29(9), 1091–1099. http://doi.org/10.1002/humu.20831.Microarray-based
dc.sourceIshikawa, Y., Bach, J. R., & Minami, R. (n.d.). Cardioprotection for Duchenne ’ s muscular dystrophy, (Dcm).
dc.sourceKoenig, M; Monaco, P; Kungel, L. M. (1988). The complete sequence of Dystrophin predicts a Rod-Shaped cytoskeletal protein. Cell, Vol 53.
dc.sourceKole, R., & Leppert, B. J. (2012). Targeting mRNA splicing as a potential treatment for Duchenne muscular dystrophy. Discovery Medicine. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22846203
dc.sourceLi, X., Zhao, L., Zhou, S., Hu, C., Shi, Y., Shi, W., … Wang, Y. (2015). A comprehensive database of Duchenne and Becker muscular dystrophy patients (0–18 years old) in East China. Orphanet Journal of Rare Diseases, 10(1), 5. http://doi.org/10.1186/s13023-014-0220-7
dc.sourceLochm, H., Lynn, S., Roy-toole, C., Braun, S., Board, T. G., Meeting, T. O. C., … Nmds, M. (2014). CHARTER FOR THE TREAT-NMD PATIENT DATABASE / REGISTRY, (October 2007).
dc.sourceLynn, S., Aartsma-Rus, A., Bushby, K., Furlong, P., Goemans, N., De Luca, A., … Straub, V. (2015). Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy. Neuromuscular Disorders, 25(1), 96–105. http://doi.org/10.1016/j.nmd.2014.09.003
dc.sourceMah, J. K., Korngut, L., Dykeman, J., Day, L., Pringsheim, T., & Jette, N. (2014). A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscular Disorders : NMD, 24(6), 482–91. http://doi.org/10.1016/j.nmd.2014.03.008
dc.sourceMinisterio de Salud y Protección Social Departamento Administrativo de Ciencia Tecnología e Innovación - Colciencias. (2015). Guía De Práctica Clínica Gpc. Guía de práctica clínica para la detección temprana, atención integral, seguimiento y rehabilitación de pacientes con diagnóstico de distrofia muscular. Retrieved from www.cenetec.salud.gob.mx
dc.sourceMoizard, M. P., Billard, C., Toutain, A., Berret, F., Marmin, N., & Moraine, C. (1998). Are Dp71 and Dp140 brain dystrophin isoforms related to cognitive impairment in Duchenne muscular dystrophy? American Journal of Medical Genetics, 80(1), 32–41. http://doi.org/10.1002/(SICI)1096-8628(19981102)80:1<32::AID-AJMG6>3.0.CO;2-Y
dc.sourceMuntoni, F., Torelli, S., & Ferlini, A. (2003a). Dystrophin and mutations: one gene, several proteins, multiple phenotypes. The Lancet Neurology, 2(12), 731–740. http://doi.org/10.1016/S1474-4422(03)00585-4
dc.sourceMuntoni, F., Torelli, S., & Ferlini, A. (2003b). Dystrophin and mutations: One gene, several proteins, multiple phenotypes. Lancet Neurology, 2(12), 731–740. http://doi.org/10.1016/S1474-4422(03)00585-4
dc.sourceNa, S.-J., Kim, W.-J., Kim, S. M., Lee, K. O., Yoon, B., & Choi, Y.-C. (2013). Clinical, immunohistochemical, Western blot, and genetic analysis in dystrophinopathy. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia, 20(8), 1099–105. http://doi.org/10.1016/j.jocn.2012.09.021
dc.sourceNakabayashi, A., Sueoka, K., Tajima, H., Sato, K., Sakamoto, Y., & Katou, S. (2007). Well-devised quantification analysis for duplication mutation of Duchenne muscular dystrophy aimed at preimplantation genetic diagnosis, 233–240. http://doi.org/10.1007/s10815-007-9111-3
dc.sourceNakamura, H., Kimura, E., Mori-Yoshimura, M., Komaki, H., Matsuda, Y., Goto, K., … Kawai, M. (2013). Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy). Orphanet Journal of Rare Diseases, 8, 60. http://doi.org/10.1186/1750-1172-8-60
dc.sourceNarvaja, E., & Luisa, M. (2012). Implementación de la Prueba del Multiplex PCR para el Gen DMD en Pacientes con sospecha de Distrofia Muscular de Duchenne / Becker y la identificación de una deleción de los exones 48-51 Establishment of the Multiplex PCR test for the DMD gene in patients.
dc.sourcePane, M., Fanelli, L., Mazzone, E. S., Olivieri, G., D’Amico, A., Messina, S., … Mercuri, E. (2015). Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test. Neuromuscular Disorders, 25(10), 749–753. http://doi.org/10.1016/j.nmd.2015.07.009
dc.sourcePane, M., Lombardo, M. E., Alfieri, P., D’Amico, A., Bianco, F., Vasco, G., … Mercuri, E. (2012). Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation. The Journal of Pediatrics, 161(4), 705–9.e1. http://doi.org/10.1016/j.jpeds.2012.03.020
dc.sourcePane, M., Scalise, R., Berardinelli, A., D’Angelo, G., Ricotti, V., Alfieri, P., … Mercuri, E. (2013). Early neurodevelopmental assessment in Duchenne muscular dystrophy. Neuromuscular Disorders : NMD, 23(6), 451–5. http://doi.org/10.1016/j.nmd.2013.02.012
dc.sourcePillers, D.-A. M. (2014). A new day for Duchenne’s?: The time has come for newborn screening. Molecular Genetics and Metabolism, 113(1-2), 11–3. http://doi.org/10.1016/j.ymgme.2014.06.001
dc.sourceRangel, V., Martin, A. S., & Peay, H. L. (2012, January). DuchenneConnect Registry Report. PLoS Currents. http://doi.org/10.1371/currents.RRN1309
dc.sourceRodino-klapac, L. R., & Mendell, J. R. (2013). Update on the Treatment of Duchenne Muscular Dystrophy, 1–7. http://doi.org/10.1007/s11910-012-0332-1
dc.sourceRomitti, P. A., Zhu, Y., Puzhankara, S., James, K. A., Nabukera, S. K., Zamba, G. K., … Bolen, J. (2015). Prevalence of Duchenne and Becker muscular dystrophies in the United States. Pediatrics, 135(3), 513–521. http://doi.org/10.1542/peds.2014-2044
dc.sourceS.J. White, et al. (2006). Duplications in the DMD Gene. Human Mutation, 27(September), 938–945. http://doi.org/10.1002/humu
dc.sourceSantos, R., Gonçalves, A., Oliveira, J., Vieira, E., Vieira, J. P., Evangelista, T., … Bronze-da-Rocha, E. (2014). New variants, challenges and pitfalls in DMD genotyping: implications in diagnosis, prognosis and therapy. Journal of Human Genetics, (February), 1–11. http://doi.org/10.1038/jhg.2014.54
dc.sourceSilva, C. T., Sc, M., Fonseca, D., Restrepo, C. M., Contreras, N. C., & Mateus, H. E. (2004). Colombia Médica Colombia M é dica, 35, 191–198.
dc.sourceSoltanzadeh, P., Friez, M. J., Dunn, D., von Niederhausern, A., Gurvich, O. L., Swoboda, K. J., … Flanigan, K. M. (2010). Clinical and genetic characterization of manifesting carriers of DMD mutations. Neuromuscular Disorders : NMD, 20(8), 499–504. http://doi.org/10.1016/j.nmd.2010.05.010
dc.sourceSpurney, C. F. (2011). Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions. Muscle & Nerve, 44(1), 8–19. http://doi.org/10.1002/mus.22097
dc.sourceSpurney, C., Shimizu, R., Morgenroth, L. P., Kolski, H., Gordish-Dressman, H., & Clemens, P. R. (2014). Cooperative international neuromuscular research group duchenne natural history study demonstrates insufficient diagnosis and treatment of cardiomyopathy in duchenne muscular dystrophy. Muscle and Nerve, 50(2), 250–256. http://doi.org/10.1002/mus.24163
dc.sourceTakeshima, Y., Yagi, M., Okizuka, Y., Awano, H., Zhang, Z., Yamauchi, Y., … Matsuo, M. (2010). Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. Journal of Human Genetics, 55(6), 379–388. http://doi.org/10.1038/jhg.2010.69
dc.sourcevan Deutekom, J. C. T., & van Ommen, G.-J. B. (2003). Advances in Duchenne muscular dystrophy gene therapy. Nature Reviews. Genetics, 4(10), 774–783. http://doi.org/10.1038/nrg1180
dc.sourceWilton, S. D., Fletcher, S., & Flanigan, K. M. (2014). Dystrophin as a therapeutic biomarker: Are we ignoring data from the past? Neuromuscular Disorders, 24(6), 463–466. http://doi.org/10.1016/j.nmd.2014.03.007
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectDistrofia muscular de Duchenne
dc.subjectDistrofia muscular de Becker
dc.subjectDistrofinopatías
dc.titleRegistro de pacientes con distrofinopatías en Colombia
dc.typemasterThesis


Este ítem pertenece a la siguiente institución